AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
You may also be interested in...
The appointment of oncologist Thomas Lynch to succeed Francis Cuss as Chief Scientific Officer suggests the biopharma won’t be straying too far from its current focus on developing cancer drugs.
AstraZeneca played it straight when reporting a strong second quarter, outlining a robust late stage pipeline, a growing list of early assets and collaborations, while avoiding “the elephant in the room” - predator Pfizer’s paused-pursuit of the U.K. pharma.
AstraZeneca’s business development executives sit down with “The Pink Sheet” and talk about their process, almost being acquired, and partnering at the BIO convention in 2014.